Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 47, Issue 12, 2008, Pages 1375-1383

  Witt, Kristine L ^a,e   Shelby, Michael D ^a   Itchon Ramos, Nilda ^b   Faircloth, Melissa ^b   Kissling, Grace E ^a   Chrisman, Allan K ^b   Ravi, Hima ^b   Murli, Hemalatha ^c   Mattison, Donald R ^d   Kollins, Scott H ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Covance Laboratories ^*

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Chromosome aberrations; Cohort study; Micronuclei; Sister chromatid exchanges; Stimulant drugs

Indexed keywords

AMPHETAMINE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD SAMPLING; CELL DAMAGE; CHILD; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICRONUCLEUS; PATIENT COMPLIANCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SISTER CHROMATID EXCHANGE;

EID: 57749195081     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/CHI.0b013e3181893620     Document Type: Article

References (39)

1. Safer DJ. Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry. 2000;12:55-62.
2. Safer DJ, Malever M. Stimulant treatment in Maryland public schools. Pediatrics. 2000;106:533-539.
3. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA. Psychotherapeutic medication patterns for youths with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 1999;153:1257-1263.
4. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030.
5. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord. 2007;10:335-342.
6. Dulcan MK, Benson RS. AACAP Official Action. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J Am Acad Child Adolesc Psychiatry. 1997;36:1311-1317.
7. Biederman J, Spencer TJ, Wilens TE, Prince JB, Faraone SV. Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry. 2006;45:1147-1150.
8. Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(5):706-712
9. Faraone SV. Stimulant therapy in the management of ADHD: mixed amphetamine salts (extended release). Expert Opin Pharmacother. 2007;8:2127-2134.
10. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999;38:503-512.
11. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1448.
12. El-Zein RA, Abdel-Rahman SZ, Hay MJ, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 2005;230:284-291.
13. Bonassi S, Znaor A, Norppa H, Hagmar L. Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective. Cytogenet Genome Res. 2004;104:376-382.
14. Bonassi S, Znaor A, Ceppi M, et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis. 2007;28:625-631.
15. Preston RJ, Kollins SH, Swanson JM, et al. Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett. 2005;230:292-294.
16. El-Zein RA, Hay MJ, Lopez MS, et al. Response to comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al. Cancer Lett. 2006;231(1):146-148.
17. Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, Zeiger E. Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ Mutagen. 1986;8(Suppl 7):1-119.
18. Galloway SM, Armstrong MJ, Reuben C, et al. Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluations of 108 chemicals. Environ Mol Mutagen. 1987;10(Suppl 10):1-175.
19. Teo SK, San RH, Wagner VO, et al. D-Methylphenidate is non-genotoxic in in vitro and in vivo assays. Mutat Res. 2003;537:67-79.
20. National Toxicology Program. Toxicology and Carcinogenesis Studies of Methylphenidate Hydrochloride (CAS no. 298-59-9) in F344/N Rats and B6C3F1 Mice (Feed studies). Technical Report Series No. 439. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. Research Triangle Park: U.S. Department of Health and Human Services; 1995.
21. Suter W, Martus HJ, Elhajouji A. Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test. Mutat Res. 2006;607:153-159.
22. Walitza S, Werner B, Romanos M, Warnke A, Gerlach M, Stopper H. Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? Environ Health Perspect. 2007;115:936-940.
23. Jacobson-Kram D, Mattison D, Shelby M, Slikker W, Tice R, Witt K. Methylphenidate and chromosome damage. Cancer Lett. 2008;260:216-218.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4th ed. Washington: American Psychiatric Association; 2000.
25. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(Suppl 10):85S-121S.
26. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
27. Conners CK. Conners Rating Scales - Revised. Technical Manual. North Tonawanda: Multi-Health Systems; 1997.
28. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry. 2000;39:28-38.
29. FDA Guidelines, Good Laboratory Practice, Part 58. Title 21. Code of Federal Regulations.
30. Conover WJ. Practical Nonparametric Statistics. New York: John Wiley & Sons; 1971.
31. Bender MA, Preston RJ, Leonard RC, Pyatt BE, Gooch PC. Chromosomal aberration and sister-chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample. II. Extension of age range. Mutat Res. 1989;212:149-154.
32. Neri M, Ceppi M, Knudsen LE, et al. Baseline micronuclei frequency in children: estimates from meta- and pooled analyses. Environ Health Perspect. 2005;113:1226-1229.
33. Volkow ND, Insel TR. What are the long-term effects of methylphenidate treatment? Biol Psychiatry. 2003;54:1307-1309.
34. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998;31:533-544.
35. Mick E, Biederman J, Faraone SV. Comment on Lambert and Hartsough (1998). J Learn Disabil. 2000;33:314; author reply 314-316.
36. Oestreicher N, Friedman GD, Jiang SF, Chan J, Quesenberry C Jr, Habel LA. Methylphenidate use in children and risk of cancer at 18 sites: results of surveillance analyses. Pharmacoepidemiol Drug Saf. 2007;16:1268-1272.
37. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 1989;49:5736-5747.
38. Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manag Care Pharm. 2007;13:561-569.
39. Witt KL, Cunningham CK, Patterson KB, et al. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen. 2007;48:322-329.